Fri, Aug 22, 2014, 1:29 PM EDT - U.S. Markets close in 2 hrs 31 mins

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • bimenow_99 bimenow_99 Mar 11, 2004 12:06 PM Flag

    JNJ's deal with Guidant..

    Does that not mean CYPHER stent is inferior to
    Taxus? If JNJ could compete effectively with
    BSX, you would think they would not sign on
    with Guidant.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I have a question for leagueeg324, your post #25793 indicated you knew a lot about the Steeplechaser. Please this is not an argument, this is trying to get a response on a question I have asked several times. That is I have tried to find any information on the Steeplechase and except for it being referenced by JNJ, I have not heard about it in a non-DES version, or a DES version to date in any country. I guess what i am asking is where is the stent, or could it be that JNJ does not have a viable next generation stent and that also was a factor in the JNJ/GDT deal. I still see that deal as 100% upside for GDT, and as a realization that if they want to stay in this market they needed help. One thing i do believe that it is not easy to get a DES stent to market as proven by the fact that most attempts have failed, and only two have been successful. I have no doubt that the GDT deal will help JNJ with sales of Cypher. I believe that the next DES stent on the market will be the Liberte, followed closely by a DES Vision stent. Timing will be dependant on what the FDA will require. If the FDA requires a complete study, than i would assume the same would apply to the Vision. If the FDA does require a full study, than whether it be the Liberte or the Vision, I see a time table of a Spring study, 2-3 months, 9 month F/U, and that makes it end of '05 as the earliest date. Thoughts?

    • "I called the labs I use to work in, and I stopped by to talk to a few docs today who live in our neighborhood and that I have known for a long time, and all said that Taxus is just sitting on the shelf at the hospital waiting for someone to use them"

      THIS MESSAGE IS ABSOLUTE BS. The BSX reps are only allowed to open 1-2 labs per week and the product has been out 1 week. The first labs were babysat and GDT/JNJ reps were not allowed in as a rule. Taxus stents flew off the shelves and were quickly replaced!!!!

      All indications are that the launch has been going smoothly. I saw a lab receive 150 Taxus stents and put the Cyphers in the same boxes to return to Miami Lakes.

      R3

      Still long and strong, though no longer predicting 70% in 70 days. I now believe 50% in 70 days. I respect the power of GDT. I believe that once the EVT lawsuits are resolved, JNJ will buy GDT. Right now, too much potential for large liability that insurance may not cover due to criminal behavior with regards to the GDT AAA graft.

    • << I called the labs I use to work in, and I stopped by to talk to a few docs today who live in our neighborhood and that I have known for a long time, and all said that Taxus is just sitting on the shelf at the hospital waiting for someone to use them. >>


      I would like to think this is a credible post, but weren't you the same person who was wondering about where the name Taxus came from? (paclitaxel, btw)

      What type of work did you once perform in the cath lab? What are you doing now?

    • I called the labs I use to work in, and I stopped by to talk to a few docs today who live in our neighborhood and that I have known for a long time, and all said that Taxus is just sitting on the shelf at the hospital waiting for someone to use them. Yes, one of the labs is one of the major "Core Lab" for many studies, but they continue to use the J&J product out of habit (e.g. use to reaching for the stents on the bottom shelf whereas the Taxus stents are now on the top shelf). Now, I would not call that a very scientific approach, but it provides some feedback.

    • Hey chrom , if you can trade the ASX there is a cancer drug in phase 1 /2a trials which has been used on 40+ special access patients(chemo resistent , inoperable months to live ) with great success . Results up to tumor eradication .
      Little side effects , and after these trials are done later this year the plan is phase 2 against mesothelioma and metastatic melanoma . It works against most cancers , but success against those two cancers ,which it has demonstrated on special access patients , will guarantee both orphan drug and fast track . You will not have to wait another 9 years for 500% .
      The compound is SBP002
      Check it out at Solbec.com.au
      Cheers .

    • JNJ is in a mess and they are going to stay there.

      Even if they get approval for a buyout of BSTE it has nothing to do with the space they are competing with BSX in.

      That would be a non factor for any BSX shareholders.

    • I certainly do not claim knowledge of metals. Logic tells me that over time metals other than stainless Steel will be be found to have fewer trade offs. My knowledge of the Vision having a recoil problem is what I heard in a poker game! I understand recoil from a clinical perspectve. Since I heard it from people I know, I thought, write it on the board and in no time I will probably get educated on the vision. Like I have said before, this board was a friendly, fiesty, had great debates, and we argued, but we were not mad, or pissed off.

    • JNJ is a mess right now. They have their hands in everything and are over reaching their grasps.

      BSX will dominate the markets and leave JNJ to wonder what went wrong.

      If JNJ steps into the BNP Triage market with a buyout of BSTE they will plunge even further into chaos.

    • Recoil is not something that you would expect from a material with a lower elastic limit than stainless steel. But we are speaking in generalities and without the numbers there is no point in discussing this further other that in general it seems to be in conflict with I remember. Or it could be the configuration of the stent that could cause the observation of recoil.

      The GDT-JNJ alliance it might be as you say but I still think that the only thing that makes sense to me is Cordis being spun off to GDT.

    • OK; But I understand that there are some people sensitive to Nickle that has prompted companies to look for Nickle free alloys.

      Have also heard of patients complain of a "Metal taste in their mouth" - Could this be due to Nickle????

      Could this sensitivity be a driving factor for a new composition? Don't know but could be a factor.

      Knew about Nitinol but not about the navy lab being included in the name.

    • View More Messages
 
BSX
12.51-0.15(-1.18%)1:29 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.